Activin A

Activin A Product List

  • Product Category

    Protein (7)Kits (1)

  • Product Status

    Launched (8)

  • Species

    Human (8)

  • Tag

    His Tag (1)Tag Free (6)- (1)

  • Conjugate

    Unconjugated (7)- (1)

Activin A Background

Activin and inhibin are two closely related protein complexes that have almost directly opposite biological effects. Activin enhances FSH biosynthesis and secretion, and participates in the regulation of the menstrual cycle. Many other functions have been found to be exerted by activin, including roles in cell proliferation, differentiation, apoptosis, metabolism, homeostasis, immune response, wound repair, and endocrine function. Conversely inhibin down regulates FSH synthesis and inhibits FSH secretion.Activins are nonglycosylated homodimers or heterodimers of various β subunits (βA, βB, βC, and βE in mammals), while Inhibins are heterodimers of a unique α subunit and one of the β subunits. Activin A is a widely expressed homodimer of two βA chains. The βA subunit can also heterodimerize with a βB or βC subunit to form Activin AB and Activin AC, respectively. The 14 kDa mature human βA chain shares 100% amino acid sequence identity with bovine, feline, mouse, porcine, and rat βA.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
BLU-782BLU-782; IPN-60130Phase 2 ClinicalBlueprint Medicines Corp, Ipsen SAMyositis Ossificans
Details
ZilurgisertibINCB-000928; INCB-00928Phase 2 ClinicalIncyte CorpPolycythemia Vera; Renal Insufficiency; Anemia; Myelodysplastic Syndromes; Ossification, Heterotopic; Multiple Myeloma; Primary Myelofibrosis; Myositis Ossificans; Thrombocythemia, Essential
Details
KER-047KER-047; TRND482477Phase 1 ClinicalNational Center For Advancing Translational SciencesAnemia, Iron-Deficiency; Myositis Ossificans
Details
ItacnosertibTP-0184Phase 1 ClinicalTolero Pharmaceuticals Inc, Sumitomo DainipponSolid tumours; Anemia
Details
BCX-9250BCX-9250Phase 1 ClinicalBiocryst Pharmaceuticals IncMyositis Ossificans
Details
HS135HS-135Phase 1 Clinical35Pharma IncHypertension, Pulmonary; Heart Failure, Diastolic; Pulmonary Arterial Hypertension
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Momelotinib DihydrochlorideCYT-387; GS-0387; GSK-3070785ApprovedGilead Sciences Inc, Cytopia Pty LtdOjjaara, OmjjaraUnited StatesPrimary Myelofibrosis; AnemiaGlaxosmithkline Llc, Glaxosmithkline Plc2023-09-15Polycythemia Vera; Anemia; Myelodysplastic Syndromes; Neoplasms; Myeloproliferative Disorders; Pancreatic Intraductal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Splenomegaly; Thrombocythemia, Essential; Carcinoma, Non-Small-Cell Lung
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information